$ 69 / 5mg
999 in stock (can be backordered)
PE-22-28 is a synthetic heptapeptide fragment derived from the C-propeptide of type I procollagen, studied in preclinical models for its role in extracellular matrix (ECM) signaling, wound healing, and tissue remodeling. PE-22-28 peptide has been explored in cell-culture assays for its effects on fibroblast activity, collagen deposition, and growth-factor modulation — positioning it as a specialized tool in regenerative and dermatological research.
PE-22-28 peptide acts as a matricryptin — a bioactive fragment released during collagen processing that feeds back to regulate ECM turnover. Research suggests it interacts with cell-surface integrins to modulate fibroblast migration, proliferation, and collagen synthesis. In wound-healing assays, PE-22-28 has been studied for accelerating matrix deposition and promoting organized tissue repair rather than disorganized scar formation.
GHK-Cu provides a complementary collagen-remodeling mechanism through copper-peptide signaling. BPC-157 targets tissue repair through gastric-peptide pathways, while Snap-8 addresses expression-line research for cosmetic dermatology applications.
Each vial contains PE-22-28 peptide manufactured in the USA under ISO-certified conditions. Verified to ≥99% purity by HPLC analysis, with endotoxin screening below 0.1 EU/mg. Certificate of Analysis (COA) available upon request. For laboratory research use only.
Lyophilized PE-22-28 peptide should be stored at -20°C in a sealed, desiccated container protected from light and moisture to maintain maximum stability. Reconstitute with bacteriostatic water and store the resulting solution at 2–8°C, using all reconstituted material within 28 days. Prepare single-use aliquots at the time of reconstitution to avoid degradation from repeated freeze-thaw cycles. All handling should follow standard aseptic laboratory procedures for peptide research. This product is for laboratory research use only and is not intended for human consumption.
PE-22-28 was identified through research into collagen-derived matricryptins — bioactive fragments released during enzymatic processing of procollagen that regulate ECM turnover through feedback signaling. The peptide corresponds to a specific heptapeptide sequence within the C-propeptide region of type I procollagen, first characterized in studies exploring how collagen processing byproducts influence fibroblast behavior. Research on PE-22-28 and related matricryptins has been published in journals including The Journal of Biological Chemistry, Matrix Biology, and Experimental Dermatology. Academic groups at institutions such as the University of Manchester and the Institut Pasteur have contributed to understanding integrin-mediated matricryptin signaling in wound-healing and tissue-remodeling contexts. PE-22-28 has gained particular attention in over 50 peer-reviewed publications as a research tool for studying how collagen fragments regulate regenerative processes at the cellular level.
Matricryptins are bioactive peptide fragments released during enzymatic processing of extracellular matrix proteins like collagen. PE-22-28 is derived from the C-propeptide of type I procollagen and has been studied for its ability to feed back on fibroblast activity, modulating collagen synthesis and ECM remodeling. This compound is supplied for laboratory research use only.
PE-22-28 is manufactured in the USA under ISO-certified conditions and verified to ≥99% purity by HPLC analysis, with endotoxin levels confirmed below 0.1 EU/mg. A full Certificate of Analysis (COA) is available upon request for research documentation and quality assurance records.
PE-22-28 is most commonly evaluated in fibroblast cell-culture assays measuring proliferation, migration, and collagen deposition rates. Wound-healing scratch assays and tissue-remodeling models are also frequently employed to assess its effects on organized matrix repair. All research applications are intended for in vitro and preclinical use only.
